… to an end to the drug’s current life cycle after … drug portfolio for functional and motility disorders
(FMD). It is also disappointing for those expecting line extensions of this drug for functional …

… the gastroenterologist a comprehensive summary of the … Cisapride was introduced worldwide
in the 1990s as a serotonin 5-… this withdrawal of tegaserod was a report by the Swiss drug …

… issues associated with alosetron and tegaserod (key drugs … The serotonin signalling system:
from basic understanding to … through the gut wall), by removal of 5-HT via the vasculature …

… Results: Tegaserod was withdrawn in 2007 due to increased … and mucosal application of
serotonin activates local reflex … a concise summary of the abovementioned drugs used for …

… of the gut, including motility, secretion, visceral perception, and … The 5-HT4 agonist tegaserod
elicits visceral analgesia in … as a gastrokinetic agent until its withdrawal in 2000. This 5-HT4 …

… In addition, the withdrawal of alosetron from the market … ability of serotonergic compounds
(alosetron and tegaserod) to … In summary, whilst it is clear that drugs acting at 5-HT receptors …

… Although both of these drugs have now been withdrawn … with colonic motility under both
fasting and fed conditions [10]. One … Response rates to Tegaserod were significantly higher in …

… tegaserod, though effective, were ultimately withdrawn due to cardiovascular adverse events
due in part to receptor non-selectivity. Highly selective serotonergic … a plausible explanation …

… Opioid as well as serotonin [5-hydroxytryptamine (5-HT)] receptors also regulate … neurons
in vitro, tegaserod never achieved registration in Europe and has been withdrawn shortly in the …

… summarizes recent progress in drug development for FD. … FD were treated for 6 weeks with
tegaserod 6 mg bid (twice a day… For instance, the serotonin reuptake inhibitor paroxetine was …